Retinal Vein Occlusion Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Retinal Vein Occlusion Market Trends and Insights

Aging-Related and Cardio-Metabolic Risk Expansion

Population aging and the rise of cardiometabolic disease are creating a structural increase in the at-risk pool for the retinal vein occlusion market. RVO incidence doubled after age 50 and reached 4.6 per 1,000 in people older than 80 years, which was a 20-fold increase over the 40 to 49 cohort. In East Asian populations, hypertension carried an odds ratio of 4.11 and chronic kidney disease carried an odds ratio of 4.14 for RVO. The 2025 Gutenberg Health Study also showed that CRVO patients faced a 3.83-fold elevated mortality risk independent of traditional cardiovascular factors. This is widening screening and referral activity beyond ophthalmology and bringing more patients into earlier retinal evaluation.^{[1]Anna Maria Voigt, Hisham Elbaz, Elsa Wilma Böhm, et al., “Incidence of Retinal Vein Occlusion and Its Association with Mortality, Results from the Gutenberg Health Study,” Ophthalmology, aaojournal.org}

Anti-VEGF Standard-Of-Care Persistence

Anti-VEGF therapy kept its central role in the retinal vein occlusion market because the 2024 American Academy of Ophthalmology Preferred Practice Pattern continued to place intravitreal anti-VEGF agents at the front of care for macular edema secondary to RVO. The clinical need behind this position is durable, since up to 70% of eyes in the LEAVO trial showed persistent or recurrent macular fluid over 100 weeks. That pattern means repeat dosing remains necessary for a large share of patients even after the initial response phase.^{[2]Christiana Dinah et al., “What Is Occluding Our Understanding of Retinal Vein Occlusion,” Ophthalmology and Therapy, link.springer.com} Price competition can change product mix, but it does not remove the underlying need for ongoing injections when fluid persists. This gives the segment a durable demand floor even as therapy choice becomes more varied.

New Approvals and Durability-Led Regimen Expansion

The retinal vein occlusion market is being reshaped by durability-led regimen expansion rather than by a simple rise in treatment starts. In the BALATON extension phase, 32% of faricimab patients completed 2 consecutive q16w cycles, which showed that a meaningful subset could move to a lighter treatment schedule.^{[3]Hoffmann-La Roche Limited, “VABYSMO Is Now Reimbursed in Ontario for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion,” Roche Canada, rochecanada.com} Kodiak Sciences reported that half of patients in the Phase 3 BEACON study remained injection-free through the second 6 months of treatment with tarcocimab. These durability profiles matter because they reduce clinic congestion and make follow-up care easier for smaller retina centers to absorb. The commercial and clinical value of longer intervals is therefore becoming a major point of differentiation across the treatment field.

OCT and OCTA-Led Earlier Detection and Monitoring

OCT and OCTA are moving from supportive imaging tools to decision-critical inputs across the retinal vein occlusion market. A 2025 meta-analysis that covered 2,119 RVO eyes across 53 studies confirmed that OCTA can quantify capillary nonperfusion, foveal avascular zone enlargement, and vessel density loss in a reliable manner. In CRVO, OCTA captured deeper ischemic asymmetry in 91.7% of cases, which reduced dependence on fluorescein angiography in moderate-complexity settings. This is making earlier referral easier from general ophthalmology and community optometry settings. Real-world monitoring is also improving, with one Swiss center validating AI-assisted macular fluid tracking across a 2-year follow-up period.

High Branded Biologic Cost and Repeat Injection Burden

High biologic cost and repeat intravitreal dosing still limit full treatment conversion in the retinal vein occlusion market. The chronic-care profile of anti-VEGF means many eyes need ongoing retreatment rather than a short fixed course, and persistent or recurrent macular fluid remained present in up to 70% of eyes over 100 weeks in LEAVO. By contrast, the Phase IV YANGTZE study reported a mean of 2.3 dexamethasone implant injections over 12 months in Chinese RVO patients, which helps explain why lower-procedure options remain relevant when visit burden is high. The gap between frequent retreatment need and patient capacity creates discontinuation risk in both self-pay and reimbursed settings. For that reason, pricing pressure and dosing burden remain linked restraints even when treatment efficacy is well established.

Retina-Clinic Capacity Constraints and Poor Persistence

Retina specialist capacity places a practical ceiling on how much of the retinal vein occlusion market can move from diagnosis to active treatment. A University of Tokyo study showed that starting anti-VEGF therapy more than 28 days after the first CRVO presentation was associated with statistically significant long-term vision loss, while avoiding that delay required monitoring every 1 to 2 weeks. A Swiss real-world cohort then showed that a mean 10-week interruption during COVID lockdowns caused fluid recurrence and short-term vision loss, even though 2-year outcomes were comparable. That same cohort also suggested that some eyes may not need continuous high-intensity retreatment, since 17% required no further injections after the disruption. Extended-interval regimens help relieve this bottleneck, but they do not fully solve the scheduling burden for patients who remain in monthly loading or close monitoring cycles.

*Our updated forecasts treat driver/restraint impacts as directional, not additive. The revised impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Disease Type: BRVO Dominates, CRVO Grows With Diagnostic Precision

Branch retinal vein occlusion retained 46.37% of the retinal vein occlusion market share in 2025. BRVO leads because it is 4 times more prevalent than CRVO globally, with risk clustering at the superotemporal crossing, where arterial compression is common in hypertensive patients. A pooled BRVO prevalence of 4.42 per 1,000 translates into a large clinical pool across treated and untreated patients. That structural case volume gives the retinal vein occlusion market a durable base in diagnosis, monitoring, and repeat therapy.

Central retinal vein occlusion is the fastest-growing disease subtype in the retinal vein occlusion market, with an 8.23% CAGR from 2026 to 2031. Growth is being supported by OCTA-based ischemia markers such as foveal avascular zone perimeter, which identified ischemic conversion with 88.9% sensitivity. This matters because previously missed or undertreated CRVO cases are now more likely to be escalated before neovascular complications appear. Hemiretinal vein occlusion remains the smallest segment, but its clearer recognition in clinical protocols is gradually improving diagnostic coding and treatment uptake.

By Condition: Ischemic RVO Commands Value, Non-Ischemic Builds Volume

Ischemic RVO accounted for 37.51% of the retinal vein occlusion market size in 2025. Its higher value weight reflects the greater treatment intensity that often comes with neovascular complications, where anti-VEGF, pan-retinal photocoagulation, and corticosteroids can be used together. Non-ischemic retinal vein occlusion is the fastest-growing condition subtype at a 7.93% CAGR through 2031. The larger non-ischemic patient pool is supported by the approximate 3:7 ischemic-to-non-ischemic presentation split and by the steady rise in older at-risk populations.

The retinal vein occlusion market is also changing because imaging can now separate ischemic and non-ischemic presentations earlier in the care pathway. DRIL and the prominent middle-limiting membrane sign differentiated ischemic from non-ischemic RVO in 57% and 58% of cases, respectively. These markers are useful in settings where fluorescein angiography is not always practical. Better triage can move higher-risk patients toward faster escalation when ischemic features are present.

By Treatment Modality: Anti-VEGF Leads, Laser Grows on Combination Protocols

Anti-VEGF therapy accounted for 39.98% of the retinal vein occlusion market size in 2025. Its lead position reflects AAO guidance that places intravitreal anti-VEGF agents at the center of treatment for macular edema secondary to RVO. Demand remains strong because many eyes show persistent or recurrent fluid over long follow-up, which keeps repeat dosing clinically necessary. This leaves anti-VEGF as the anchor of the retinal vein occlusion industry even as other modalities expand around it.

Laser therapy is projected to grow at an 8.85% CAGR through 2031 in the retinal vein occlusion market. The rise is tied to its role in combination use for peripheral ischemia management and for prevention of neovascular glaucoma, not to a return to routine standalone photocoagulation. A 2026 Tokyo study found that OCT and OCTA-guided focal photocoagulation achieved macular edema remission in 48.9% of BRVO-associated microaneurysm cases without anti-VEGF escalation. Corticosteroids remain the main second-line option, and the Phase IV YANGTZE study reported a mean of 2.3 dexamethasone implant injections over 12 months in Chinese patients.

By End User: Hospitals Anchor Revenue While Clinics Capture New Growth

Hospitals held 41.99% of the retinal vein occlusion market in 2025. They remain the main site for first diagnosis, initial loading therapy, and complex presentations that involve vitreous hemorrhage or neovascular glaucoma. This keeps hospitals central to revenue generation even as more routine follow-up is redistributed. The retinal vein occlusion industry still depends on hospital systems for advanced imaging access, emergency assessment, and surgical backup.

Ophthalmology clinics and retina centers are projected to expand at a 10.02% CAGR through 2031. Their gain is tied to longer interval regimens that lower scheduling pressure for repeat visits. Roche Canada reported that 32% of faricimab patients completed 2 consecutive q16w cycles in the BALATON extension phase, which shows how selected patients can be managed within lighter outpatient workflows. Ambulatory surgical centers continue to support laser and combination procedures when compliance and billing rules allow those services to be delivered outside hospitals.

Geography Analysis

North America accounted for 36.43% of the retinal vein occlusion market share in 2025. The region benefits from established retina specialist networks, strong adoption of AAO-guided anti-VEGF care, and broad access to advanced imaging. Canada widened public access in 2025 when faricimab reimbursement expanded in Ontario and Quebec. That expansion extends access beyond private insurance and supports treatment continuity for RVO-related macular edema. North America therefore remains the reference market for high-value biologic use and structured follow-up care.

Europe held the second-largest share of the retinal vein occlusion market in 2025. Access is being shaped by national reimbursement pathways rather than a single regional decision, which creates uneven but expanding uptake. France issued a positive faricimab reimbursement decision, and Spain published a therapeutic positioning report that recognized faricimab as an equivalent first-line alternative to ranibizumab and aflibercept. This mix of national assessments is likely to sustain differences in treatment access and pricing across the region.

Asia-Pacific is projected to record the fastest growth in the retinal vein occlusion market, with a 9.18% CAGR through 2031. Growth is supported by a large future patient base in Asia, by China’s expanding retinal care pathway, and by Japan’s evidence that delayed anti-VEGF initiation beyond 28 days can worsen long-term vision outcomes. The Phase IV YANGTZE study also showed strong 12-month follow-up completion in Chinese patients on dexamethasone implant therapy, which points to strengthening treatment infrastructure in hospital-based ophthalmology. Middle East, Africa, and South America remain smaller contributors, but government-led retinal screening in GCC systems and Mexico’s public assessment of aflibercept point to a gradual build-out of access models outside the largest regions.